Literature DB >> 19406765

Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.

M Riva1, V N Ikonomidou, J J Ostuni, P van Gelderen, S Auh, J M Ohayon, F Tovar-Moll, N D Richert, J H Duyn, F Bagnato.   

Abstract

BACKGROUND AND
PURPOSE: Brains of patients with multiple sclerosis (MS) characteristically have "black holes" (BHs), hypointense lesions on T1-weighted (T1W) spin-echo (SE) images. Although conventional MR imaging can disclose chronic BHs (CBHs), it cannot stage the degree of their pathologic condition. Tissue-specific imaging (TSI), a recently introduced MR imaging technique, allows selective visualization of white matter (WM), gray matter (GM), and CSF on the basis of T1 values of classes of tissue. We investigated the ability of TSI-CSF to separate CBHs with longer T1 values, which likely represent lesions containing higher levels of destruction and unbound water.
MATERIALS AND METHODS: Eighteen patients with MS, who had already undergone MR imaging twice (24 months apart) on a 1.5T scanner, underwent a 3T MR imaging examination. Images acquired at 1.5T included sequences of precontrast and postcontrast T1W SE, T2-weighted (T2W) SE, and magnetization transfer (MT). Sequences obtained at 3T included precontrast and postcontrast T1W SE, T2W SE, T1 inversion recovery prepared fast spoiled gradient recalled-echo (IR-FSPGR) and TSI. A BH on the 3T-IR-FSPGR was defined as a CBH if seen as a hypointense, nonenhancing lesion with a corresponding T2 abnormality for at least 24 months. CBHs were separated into 2 groups: those visible as hyperintensities on TSI-CSF (group A), and those not appearing on the TSI-CSF (group B).
RESULTS: Mean MT ratios of group-A lesions (0.22 +/- 0.06, 0.13-0.35) were lower (F(1,13) = 60.39; P < .0001) than those of group-B lesions (0.32 +/- 0.03, 0.27-0.36).
CONCLUSIONS: Group-A lesions had more advanced tissue damage; thus, TSI is a potentially valuable method for qualitative and objective identification.

Entities:  

Mesh:

Year:  2009        PMID: 19406765      PMCID: PMC5613286          DOI: 10.3174/ajnr.A1573

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  41 in total

Review 1.  T1 hypointensities and axonal loss.

Authors:  F Barkhof; G B Karas; M A van Walderveen
Journal:  Neuroimaging Clin N Am       Date:  2000-11       Impact factor: 2.264

2.  Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.

Authors:  N D Richert; J L Ostuni; C N Bash; T P Leist; H F McFarland; J A Frank
Journal:  Mult Scler       Date:  2001-02       Impact factor: 6.312

3.  T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

Authors:  F Barkhof; J H van Waesberghe; M Filippi; T Yousry; D H Miller; D Hahn; A J Thompson; L Kappos; P Brex; C Pozzilli; C H Polman
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

4.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

5.  Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis.

Authors:  Francesca Bagnato; John A Butman; Carlos A Mora; Shiva Gupta; Yoshima Yamano; Talin A Tasciyan; Jeffrey M Solomon; Waldyr J Santos; Roger D Stone; Henry F McFarland; Steven Jacobson
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

6.  Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

Authors:  M Filippi; M Rovaris; M A Rocca; M P Sormani; J S Wolinsky; G Comi
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

7.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

8.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

Authors:  Frederik Barkhof; Wolfgang Bruck; Corline J A De Groot; Elisabeth Bergers; Sandra Hulshof; Jeroen Geurts; Chris H Polman; Paul van der Valk
Journal:  Arch Neurol       Date:  2003-08

9.  The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.

Authors:  P A Brex; P D Molyneux; P Smiddy; F Barkhof; M Filippi; T A Yousry; D Hahn; Y Rolland; O Salonen; C Pozzilli; C H Polman; A J Thompson; L Kappos; D H Miller
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

10.  T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study.

Authors:  M Sailer; N A Losseff; L Wang; M L Gawne-Cain; A J Thompson; D H Miller
Journal:  Eur J Neurol       Date:  2001-01       Impact factor: 6.089

View more
  15 in total

1.  7T MRI-Histologic Correlation Study of Low Specific Absorption Rate T2-Weighted GRASE Sequences in the Detection of White Matter Involvement in Multiple Sclerosis.

Authors:  Francesca Bagnato; Simon Hametner; David Pennell; Richard Dortch; Adrienne N Dula; Siddharama Pawate; Seth A Smith; Hans Lassmann; John C Gore; Edward B Welch
Journal:  J Neuroimaging       Date:  2015-04-21       Impact factor: 2.486

2.  Intensity ratio to improve black hole assessment in multiple sclerosis.

Authors:  Gautam Adusumilli; Kathryn Trinkaus; Peng Sun; Samantha Lancia; Jeffrey D Viox; Jie Wen; Robert T Naismith; Anne H Cross
Journal:  Mult Scler Relat Disord       Date:  2017-12-02       Impact factor: 4.339

3.  T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.

Authors:  C Thaler; T D Faizy; J Sedlacik; B Holst; K Stürner; C Heesen; J-P Stellmann; J Fiehler; S Siemonsen
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-10       Impact factor: 3.825

4.  Heterogeneity of Multiple Sclerosis White Matter Lesions Detected With T2*-Weighted Imaging at 7.0 Tesla.

Authors:  Bing Yao; Vasiliki N Ikonomidou; Fredric K Cantor; Joan M Ohayon; Jeff Duyn; Francesca Bagnato
Journal:  J Neuroimaging       Date:  2015-02-06       Impact factor: 2.486

5.  Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.

Authors:  Henry F McFarland
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

6.  Evolution of tumefactive lesions in multiple sclerosis: a 12-year study with serial imaging in a single patient.

Authors:  Vasiliki N Ikonomidou; Nancy D Richert; Alexander Vortmeyer; Fernanda Tovar-Moll; Bibiana Bielekova; Natalie E Cook; Jeff H Duyn; Francesca Bagnato
Journal:  Mult Scler       Date:  2013-10       Impact factor: 6.312

7.  Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability.

Authors:  Margareta A Clarke; Dhairya A Lakhani; Sijin Wen; Si Gao; Seth A Smith; Richard Dortch; Junzhong Xu; Francesca Bagnato
Journal:  Mult Scler Relat Disord       Date:  2021-01-05       Impact factor: 4.339

8.  Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.

Authors:  Roger C Tam; Anthony Traboulsee; Andrew Riddehough; David K B Li
Journal:  Neuroimage Clin       Date:  2012-09-05       Impact factor: 4.881

9.  Untangling the R2* contrast in multiple sclerosis: A combined MRI-histology study at 7.0 Tesla.

Authors:  Francesca Bagnato; Simon Hametner; Emma Boyd; Verena Endmayr; Yaping Shi; Vasiliki Ikonomidou; Guanhua Chen; Siddharama Pawate; Hans Lassmann; Seth Smith; E Brian Welch
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

10.  T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.

Authors:  Christian Thaler; Tobias Faizy; Jan Sedlacik; Brigitte Holst; Jan-Patrick Stellmann; Kim Lea Young; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.